Orexo Sustainability Profile
Orexo AB, a leading pharmaceutical company headquartered in Sweden, focuses on developing innovative treatments for addiction and pain management. Founded in 1995, Orexo has established a strong presence in Europe and North America, with a commitment to addressing unmet medical needs through advanced drug delivery technologies. The company’s core products, including Zubsolv, a sublingual film for opioid dependence, exemplify its unique approach to patient care. Orexo's dedication to research and development has positioned it as a key player in the pharmaceutical industry, with notable achievements in improving treatment outcomes for patients struggling with addiction. With a robust pipeline and a focus on sustainable growth, Orexo continues to make significant strides in enhancing the quality of life for individuals facing complex health challenges.
DitchCarbon Score
How does Orexo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orexo's score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orexo's reported carbon emissions
In 2024, Orexo reported total carbon emissions of approximately 1,537,000 kg CO2e, a decrease from about 2,006,000 kg CO2e in 2023. The emissions breakdown for 2024 includes Scope 1 emissions of about 312,000 kg CO2e, Scope 2 emissions of approximately 366,000 kg CO2e, and Scope 3 emissions of about 859,000 kg CO2e. In 2023, the figures were approximately 273,000 kg CO2e for Scope 1, 379,000 kg CO2e for Scope 2, and about 1,354,000 kg CO2e for Scope 3. Orexo has achieved a 3% reduction in Scope 1 and 2 emissions from the base year of 2022 to 2023, primarily due to lower emissions from sales travel. This commitment to reducing emissions reflects the company's proactive approach to climate action, although no specific Science-Based Targets Initiative (SBTi) targets have been reported. The emissions data is sourced directly from Orexo AB (publ) and is not cascaded from any parent organization. The company continues to focus on sustainability and reducing its carbon footprint as part of its operational strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 284,000 | 000,000 | 000,000 |
| Scope 2 | 405,000 | 000,000 | 000,000 |
| Scope 3 | 1,573,000 | 0,000,000 | 000,000 |
How Carbon Intensive is Orexo's Industry?
How Carbon Intensive is Orexo's Location?
Orexo's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Orexo has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
